Download PDF
Semin Speech Lang 2004; 25(2): 193-204
DOI: 10.1055/s-2004-825655
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Can Drug Therapies Improve Language Functions of Individuals with Aphasia? A Review of the Evidence

Reva B. Klein1 , Martin L. Albert1
  • 1Boston University School of Medicine, VA Boston Healthcare System, Boston, Massachusetts
Further Information

Publication History

Publication Date:
07 May 2004 (online)

    Permissions and Reprints

The neurochemistry of language and the neuropharmacology of aphasia are two domains of cognitive neuroscience still in their infancy. In this article we review what is known about these two domains, especially with regard to treating aphasia with drugs. Selected neurotransmitters can improve language function in certain patients with aphasia. We discuss which neurotransmitters work for which language functions in which patients, and why.

KEYWORDS

Neurochemistry of language - neuropharmacology of aphasia - neuroanatomy of language - recovery of function - pharmacotherapy of aphasia - neurotransmitters - catecholamines - dopamine - norepinephrine - amphetamines - acetylcholine - GABA

REFERENCES

  • 1 Mettler C C. History of Medicine. Philadelphia, PA; Blackistan 1947
    Google Scholar
  • 2 Goodglass H. Understanding Aphasia. San Diego, CA; Academic Press 1993
    Google Scholar
  • 3 Geschwind N. Disconnexion syndromes in animals and man. I.  Brain. 1965;  88 237-294
    CrossrefPubMedGoogle Scholar
  • 4 Geschwind N, Levitsky W. Human brain: left-right asymmetries in temporal speech region.  Science. 1968;  161 186-187
    PubMedGoogle Scholar
  • 5 Naeser M A, Alexander M P, Helm-Estabrooks N, Levine H L, Laughlin S A, Geschwind N. Aphasia with predominantly subcortical lesion sites, description of three capsular/putaminal aphasia syndromes.  Arch Neurol. 1982;  39 2-14
    PubMedGoogle Scholar
  • 6 Grabowski T J, Andeson S W, Cooper G E. Disorders of Cognitive Function.  American Academy of Neurology Continuum. 2002;  8 64-86
    PubMedGoogle Scholar
  • 7 Naeser M, Palumbo C, Helm-Estabrooks N, Stiassing-Eder D, Albert M L. Severe nonfluency in aphasia. Role of the medial subcallosal fasciculus and other white matter pathways in recovery of spontaneous speech.  Brain. 1989;  112 1-38
    CrossrefPubMedGoogle Scholar
  • 8 Weiller C, Isensee C, Rijntjes M et al.. Recovery from Wernicke's aphasia: a positron emission tomographic study.  Ann Neurol. 1995;  37 723-732
    CrossrefPubMedGoogle Scholar
  • 9 Stein D G, Brailowsky S, Will B. Brain Repair. New York; Oxford University Press 1995
    Google Scholar
  • 10 Stein B J et al.. Acute Stroke Management. American Academy of Neurology Continuum 2003 9: 11-17
    Google Scholar
  • 11 Mimura M, Albert M L, McNamara P. Toward a pharmacotherapy for aphasia. In: Kirshner H Handbook of Neurological Speech and Language Disorders. New York; Marcel Dekker 1995: 465-482
    Google Scholar
  • 12 McNamara P, Durso R. Language functions in Parkinson's disease: evidence for a neurochemistry of language. In: Connor LT, Obler LK Neurobehavior of Language and Cognition. Studies of Normal Aging and Brain Damage. Boston, MA; Wolters Kluwer 2000: 201-212
    Google Scholar
  • 13 McNamara P, Krueger M, O'Quin K, Clark J, Durso R. Grammaticality judgment and sentence comprehension in Parkinson's disease: a comparison with Broca's aphasia.  Int J Neurosci. 1996;  86 151-166
    PubMedGoogle Scholar
  • 14 Albert M L. Toward a Neurochemistry of Naming in Language and the Brain. San Diego, CA; Academic Press 2000: 157-165
    Google Scholar
  • 15 Albert M L, Bachman D L, Morgan A, Helm-Estabrooks N. Pharmacotherapy for aphasia.  Neurology. 1988;  38 877-879
    PubMedGoogle Scholar
  • 16 Sabe L, Leiguarda R, Starkstein S E. An open-label trial of bromocriptine in nonfluent aphasia.  Neurology. 1992;  42 1637-1638
    PubMedGoogle Scholar
  • 17 Sabe L, Salvarezza F, Garcia Cuerva A, Leiguarda R, Starkstein D. A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia.  Neurology. 1995;  45 2272-2274
    PubMedGoogle Scholar
  • 18 Gupta S R, Mlcoch A G, Scolaro C, Moritz T. Bromocriptine treatment nonfluent aphasia.  Neurology. 1995;  45 2170-2173
    PubMedGoogle Scholar
  • 19 Gold M, VanDam D, Silliman E R. An open-label trial of bromocriptine in nonfluent aphasia: a qualitative analysis of work storage and retrieval.  Brain Lang. 2000;  74 141-156
    CrossrefPubMedGoogle Scholar
  • 20 McNamara P, Albert M L. Pharmacotherapy of Cognition, in Clinical Neuropsychology. 4th ed. Oxford; Oxford University Press 2003: 640-656
    Google Scholar
  • 21 Miyai I, Reding M. Antidepressant effects on recovery. In: Goldstein LB Restorative Neurology, Advances in Pharmacotherapy for Recovery After Stroke. Armonk, NY; Futura Publishing 1998: 271-286
    Google Scholar
  • 22 Valentino R J, Curtis A L, Parris D G, Wehby R G. Antidepressant actions on brain noradrenergic neurons.  J Pharmacol Exp Ther. 1990;  253 833-840
    PubMedGoogle Scholar
  • 23 Robinson R G, Bolduc P L, Price T R. Two-year longitudinal study of poststroke mood disorders. Diagnosis and outcome at one and two years.  Stroke. 1987;  18 837-843
    PubMedGoogle Scholar
  • 24 Finklestein S P, Weintraub R J, Karmouz N, Askinazi C, Davar G, Baldessarini R J. Antidepressant drug treatment for poststroke depression. Retrospective study.  Arch Phys Med Rehabil. 1987;  68 772-776
    PubMedGoogle Scholar
  • 25 Lipsey J R, Robinson R G, Pearlson G D, Rao K, Price T R. Nortriptyline treatment of post-stroke depression: a double-blind study.  Lancet. 1984;  1 297-300
    PubMedGoogle Scholar
  • 26 Robinson R G, Kubos K L, Starr L B, Rao K, Price T R. Mood disorders in stroke patients. Importance of location of lesion.  Brain. 1984;  107 81-93
    CrossrefPubMedGoogle Scholar
  • 27 Walker-Batson D, Curtis S, Natarajan R et al.. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia.  Stroke. 2001;  32 2093-2098
    CrossrefPubMedGoogle Scholar
  • 28 Small S L. Pharmacotherapy of aphasia: a critical review.  Stroke. 1994;  25 1282-1289
    PubMedGoogle Scholar
  • 29 Benson D F. Presentation 10. In: Benton AL Behaviorial Change in Cerebrovascular Disease. New York; Harper and Row 1970 77
    Google Scholar
  • 30 Luria A R. Traumatic Aphasia. The Hague; Mouton 1970 (first published in Russian in 1947)
    Google Scholar
  • 31 Moscowitch L, McNamara P, Albert M L. Neurochemical correlates of aphasia.  Neurology. 1991;  41(suppl) 410 , (abst)
    PubMedGoogle Scholar
  • 32 Clark W M, Warach S J, Pettigrew L C, Gammans R E, Sabounjian L A. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group.  Neurology. 1997;  49 671-678
    PubMedGoogle Scholar
  • 33 Weiss G B. Metabolism and actions of CDP-choline as an endogenous compound administered exogenously as citicoline.  Life Sci. 1995;  56 637-660
    CrossrefPubMedGoogle Scholar
  • 34 Huber W, Willmes K, Poeck K, Van Vleyman B, Deberdt W. Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study.  Arch Phys Med Rehabil. 1997;  78 245-250
    CrossrefPubMedGoogle Scholar
  • 35 Kessler J, Thiel A, Karbe H, Weiss W D. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients.  Stroke. 2000;  31 2112-2116
    CrossrefPubMedGoogle Scholar
  • 36 Tanaka Y, Miyazaki M, Albert M. Effects of increased cholinergic activity on naming in aphasia.  Lancet. 1997;  350 116-117
    PubMedGoogle Scholar
  • 37 Tanaka Y, Albert M L. Cholinergic therapy for fluent aphasia. Presented at: Annual Meeting of American Neurological Association; October 3 2001 Chicago, IL;
    Google Scholar
  • 38 Berthier M L, Hinojosa J, Martin Mdel C, Fernandez I. Open-label study of donepezil in chronic poststroke aphasia.  Neurology. 2003;  60 1218-1219
    CrossrefPubMedGoogle Scholar
  • 39 Schallert T, Hernandez T D. GABAergic drugs and neuroplasticity after brain injury: impact on functional recovery. In: Goldstein LB Restorative Neurology, Advances in Pharmacotherapy for Recovery after Stroke. Armonk, NY; Futura Publishing Company Inc 1998: 91-120
    Google Scholar
  • 40 Schallert T, Hernandez T D, Barth T M. Recovery of function after brain damage: severe and chronic disruption by diazepam.  Brain Res. 1986;  379 104-111
    CrossrefPubMedGoogle Scholar
  • 41 Schallert T, Jones T, Lindner M D. Multilevel transneuronal degeneration after brain damage. Behavioral events and effects of anticonvulsant gamma-aminobutyric acid-related drugs.  Stroke. 1990;  21(suppl III) 143-146
    PubMedGoogle Scholar
  • 42 Walker-Batson D. Pharmacotherapy in the treatment of aphasia. In: Goldstein LB Restorative Neurology, Advances in Pharmacotherapy for Recovery after Stroke. Armonk, NY; Futura Publishing Company Inc 1998: 257-270
    Google Scholar
  • 43 Reding M F, Orto L A, Winter S W, Fortuna I M, DiPonte P, McDowell F H. Antidepressant therapy after stroke. A double-blind trial.  Arch Neurol. 1986;  43 763-765
    PubMedGoogle Scholar
  • 44 Tanaka Y, Albert M L. Serotonergic therapy for aphasia. Presented at: 31st Annual Meeting of the International Neuropsychological Society; February 6 2003 Honolulu, HI;
    Google Scholar

Reva B KleinM.D. 

VA Boston Healthcare System, 150 So. Huntington Avenue (12A)

Boston, MA 02130

Email: RevaBKlein@Boston.VA.gov

      >